scPharmaceuticals Inc (SCPH)

HC Wainwright Weighs in on scPharmaceuticals Inc.'s Q2 2024 Earnings (NASDAQ:SCPH) - Defense World

Defense World

Q2 2024 Earnings Estimate for scPharmaceuticals Inc. Issued By HC Wainwright (NASDAQ:SCPH) - MarketBeat

MarketBeat

scPharmaceuticals Inc. Expected to Earn FY2027 Earnings of $1.95 Per Share (NASDAQ:SCPH) - Defense World

Defense World

scPharmaceuticals (NASDAQ:SCPH) Rating Reiterated by HC Wainwright - Defense World

Defense World

Analysts Issue Forecasts for scPharmaceuticals Inc.'s FY2026 Earnings (NASDAQ:SCPH) - Defense World

Defense World

Ratio Revelations: scPharmaceuticals Inc (SCPH)'s Financial Metrics in the Spotlight – DWinneX - The Dwinnex

The Dwinnex

scPharmaceuticals Inc. Expected to Post FY2027 Earnings of $1.95 Per Share (NASDAQ:SCPH) - MarketBeat

MarketBeat

Was anything positive for scPharmaceuticals Inc (SCPH) stock last session? – US Post News - US Post News

US Post News

scPharmaceuticals' (SCPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

MarketBeat

scPharmaceuticals (NASDAQ:SCPH) Posts Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat

MarketBeat

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates - MSN

MSN

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Yahoo Finance

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire Inc.

scPharmaceuticals reports Q1 EPS (36c), consensus (44c) - TipRanks.com - TipRanks

TipRanks

scPharmaceuticals to Present at the H.C. Wainwright 2nd - GlobeNewswire

GlobeNewswire

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire Inc.

scPharmaceuticals (SCPH) Scheduled to Post Earnings on Tuesday - Defense World

Defense World

scPharmaceuticals (SCPH) to Release Quarterly Earnings on Tuesday - MarketBeat

MarketBeat

scPharmaceuticals (SCPH) to Release Quarterly Earnings on Tuesday - MarketBeat

MarketBeat

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024 - GlobeNewswire

GlobeNewswire

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

GlobeNewswire Inc.

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Raymond James & Associates Raises Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World

Defense World

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector ... - Yahoo Finance

Yahoo Finance

scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

GlobeNewswire Inc.

SCPH Stock Quote Price and Forecast - CNN

CNN

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire Inc.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

GlobeNewswire Inc.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue - GlobeNewswire

GlobeNewswire

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 - Yahoo Finance

Yahoo Finance

scPharmaceuticals (SCPH): Furoscix, Charting A Bright Future With FDA's Nod For CKD - Seeking Alpha

Seeking Alpha

scPharmaceuticals: Furoscix Launch And Market Access; A Promising Outlook - Seeking Alpha

Seeking Alpha

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection) - GlobeNewswire

GlobeNewswire

scPharma (SCPH) Stock: Undervalued, De-Risked Cardiology Commercial Biotech - Seeking Alpha

Seeking Alpha

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients - Seeking Alpha

Seeking Alpha

Money on the Move: Vita, scPharmaceuticals, Andera and More - BioSpace

BioSpace

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree - GlobeNewswire

GlobeNewswire

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific ... - Diagnostic and Interventional Cardiology

Diagnostic and Interventional Cardiology

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure - Diagnostic and Interventional Cardiology

Diagnostic and Interventional Cardiology

3rd time lucky? ScPharmaceuticals gets decision date for twice-rejected on-body drug delivery product - FiercePharma

FiercePharma

scPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - citybiz

citybiz

Ace heart-wear store Scpharma wields proven tool for cardiac cost saving - BioWorld Online

BioWorld Online